Canada Approves Amylyx’s ALS Drug as U.S. Seeks More Time to Review
Share this @internewscast.com



Canadian health authorities approved Amylyx Pharmaceuticals Inc.’s new drug for amyotrophic lateral sclerosis, the progressive neurodegenerative disease that robs patients of their ability to move and speak.

It is the first Canadian approval since 2018 for a new drug treating the fatal condition, which is also known as Lou Gehrig’s disease.

Share this @internewscast.com
You May Also Like

IRS takes out John Doe summons on crypto prime dealer SFOX to find tax cheat customers

The Central District of California federal court entered an order Monday to…

Yield Curve Inversion Deepens And Lengthens, Upping Recession Chances

NEW YORK, NY – MARCH 06: Traders work the floor of the…

Why Guillermo and Nandor Can’t Quit Each Other According To What We Do In The Shadows’ Kayvan Novak And Harvey Guillén

What We Do In The Shadows FX As What We Do In…

Celsius Gets Permission To Sell Mined Bitcoin; Claims Lenders Lining Up

Alex Mashinsky, founder and chief executive officer of Celcius Network Ltd., during…

SkyNano Startup To Convert CO2 Into Solid Carbon: Part 1

The smoke stacks at American Electric Power’s (AEP) Mountaineer coal power plant…

Tencent Weighs Stake Sale in Chinese Delivery Giant Meituan

Tencent Holdings Ltd. is looking to sell most or all of its…

BHP Earnings Nearly Triple as Coal Prices Run Hot

ADELAIDE, Australia—BHP Group Ltd. said its annual profit nearly tripled as it…

Bitcoin price corrects after hitting a wall at a multi-month descending trendline

On Aug. 15, Bitcoin (BTC) price and the wider market corrected while…